Journal
FRONTIERS IN IMMUNOLOGY
Volume 12, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2021.693016
Keywords
CAR-T cells; inflammation; toxicities; CRS; neurotoxicity
Categories
Funding
- Intramural Research Program of the Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration
Ask authors/readers for more resources
Engineered T cell therapies like CAR-T cells have potential to treat diseases, but inflammatory toxicities pose safety risks. Research is ongoing to understand mechanisms and strategies for managing these toxicities, with key knowledge gaps for future exploration.
Engineered T cell therapies such as chimeric antigen receptor (CAR) expressing T cells (CAR-T cells) have great potential to treat many human diseases; however, inflammatory toxicities associated with these therapies present safety risks and can greatly limit its widespread use. This article briefly reviews our current understanding of mechanisms for inflammatory toxicities during CAR T-cell therapy, current strategies for management and mitigation of these risks and highlights key areas of knowledge gap for future research.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available